Cargando…

TP53 aberrations in chronic lymphocytic leukemia: an overview of the clinical implications of improved diagnostics

Chronic lymphocytic leukemia is associated with a highly heterogeneous disease course in terms of clinical outcomes and responses to chemoimmunotherapy. This heterogeneity is partly due to genetic aberrations identified in chronic lymphocytic leukemia cells such as mutations of TP53 and/or deletions...

Descripción completa

Detalles Bibliográficos
Autores principales:	Campo, Elias, Cymbalista, Florence, Ghia, Paolo, Jäger, Ulrich, Pospisilova, Sarka, Rosenquist, Richard, Schuh, Anna, Stilgenbauer, Stephan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6269313/ https://www.ncbi.nlm.nih.gov/pubmed/30442727 http://dx.doi.org/10.3324/haematol.2018.187583

Ejemplares similares

ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation
por: Malcikova, J., et al.
Publicado: (2018)

Impact of Low-Burden TP53 Mutations in the Management of CLL
por: Lazarian, Gregory, et al.
Publicado: (2022)

Comparative analysis of targeted next-generation sequencing panels for the detection of gene mutations in chronic lymphocytic leukemia: an ERIC multi-center study
por: Sutton, Lesley-Ann, et al.
Publicado: (2020)

“Double-Hit” Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes
por: Nguyen-Khac, Florence
Publicado: (2022)

Genetic profiling of CLL: a ‘TP53 addict' perspective
por: Lodé, L, et al.
Publicado: (2016)

Comparison of acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations
por: Dutta, Sayantanee, et al.
Publicado: (2022)

Detailed analysis of therapy-driven clonal evolution of TP53 mutations in chronic lymphocytic leukemia
por: Malcikova, J, et al.
Publicado: (2015)

Telomere status in chronic lymphocytic leukemia with TP53 disruption
por: Guièze, Romain, et al.
Publicado: (2016)

Outcomes in patients with chronic lymphocytic leukemia and TP53 aberration who received first-line ibrutinib: a nationwide registry study from the Italian Medicines Agency
por: Rigolin, Gian Matteo, et al.
Publicado: (2023)

Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations
por: Blanco, Gonzalo, et al.
Publicado: (2016)

B‐prolymphocytic leukemia (B‐PLL) with genetic aberrations involving MYC and TP53
por: Tamber, Gurdip Singh, et al.
Publicado: (2021)

The clinical characteristics and prognosis in adult Ph negative acute lymphoblastic leukemia with TP53 aberrations
por: Fang, Qiuyun, et al.
Publicado: (2022)

Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study
por: Schetelig, Johannes, et al.
Publicado: (2020)

Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations
por: Wierda, William G., et al.
Publicado: (2021)

An extensive molecular cytogenetic characterization in high-risk chronic lymphocytic leukemia identifies karyotype aberrations and TP53 disruption as predictors of outcome and chemorefractoriness
por: Rigolin, Gian Matteo, et al.
Publicado: (2017)

Distinct p53 phosphorylation patterns in chronic lymphocytic leukemia patients are reflected in the activation of circumjacent pathways upon DNA damage
por: Mancikova, Veronika, et al.
Publicado: (2022)

Identification and functional characterization of new missense SNPs in the coding region of the TP53 gene
por: Doffe, Flora, et al.
Publicado: (2020)

Correction to: Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: results of a prospective observational study
por: Schetelig, Johannes, et al.
Publicado: (2021)

Identification of Clinically Relevant Subgroups of Chronic Lymphocytic Leukemia Through Discovery of Abnormal Molecular Pathways
por: Taus, Petr, et al.
Publicado: (2021)

Development of chronic myelogenous leukemia in a case of chronic lymphocytic leukemia with Tp53 gene deletion
por: Gupta, A, et al.
Publicado: (2015)

Advances in treating chronic lymphocytic leukemia
por: Tausch, Eugen, et al.
Publicado: (2014)

Telomere Dysfunction in Chronic Lymphocytic Leukemia
por: Jebaraj, Billy Michael Chelliah, et al.
Publicado: (2021)

Impact Of TP53 Gene Promoter Methylation On Chronic Lymphocytic Leukemia Pathogenesis And Progression
por: Saeed, Waleed Haji, et al.
Publicado: (2019)

Therapeutic Options for Patients with TP53 Deficient Chronic Lymphocytic Leukemia: Narrative Review
por: Stefaniuk, Paulina, et al.
Publicado: (2021)

Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia
por: Quijada‐Álamo, Miguel, et al.
Publicado: (2021)

DNA methylation profiles in chronic lymphocytic leukemia patients treated with chemoimmunotherapy
por: Tsagiopoulou, Maria, et al.
Publicado: (2019)

Refractory chronic lymphocytic leukemia – new therapeutic strategies
por: Schnaiter, Andrea, et al.
Publicado: (2010)

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort
por: Miao, Yi, et al.
Publicado: (2023)

Evolution of TP53 abnormalities during CLL disease course is associated with telomere length changes
por: Olbertova, Helena, et al.
Publicado: (2022)

TP53 gene mutation analysis in chronic lymphocytic leukemia by nanopore MinION sequencing
por: Minervini, Crescenzio Francesco, et al.
Publicado: (2016)

Landscape of TP53 Alterations in Chronic Lymphocytic Leukemia via Data Mining Mutation Databases
por: Soussi, Thierry, et al.
Publicado: (2022)

Treatment with ibrutinib does not induce a TP53 clonal evolution in chronic lymphocytic leukemia
por: Cafforio, Luciana, et al.
Publicado: (2021)

TP53 Mutations and Clinical Outcome in Chronic Lymphocytic Leukemia: Is a Threshold Still Needed?
por: Bomben, Riccardo, et al.
Publicado: (2023)

TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype
por: Ramos-Campoy, Silvia, et al.
Publicado: (2022)

Revolution of Chronic Lymphocytic Leukemia Therapy: the Chemo-Free Treatment Paradigm
por: Scheffold, Annika, et al.
Publicado: (2020)

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group
por: Jaramillo, Sonia, et al.
Publicado: (2019)

T cell receptor gene repertoire profiles in subgroups of patients with chronic lymphocytic leukemia bearing distinct genomic aberrations
por: Vlachonikola, Elisavet, et al.
Publicado: (2023)

Deep targeted sequencing of TP53 in chronic lymphocytic leukemia: clinical impact at diagnosis and at time of treatment
por: Brieghel, Christian, et al.
Publicado: (2019)

The fragility index in 2010-2021 chronic lymphocytic leukemia randomized controlled trials
por: Bagacean, Cristina, et al.
Publicado: (2022)

TP53-Mutated Myelodysplasia and Acute Myeloid Leukemia
por: Testa, Ugo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_ohjgaksgaimgjrr9072vikbtlm